Physician profile
Raza Malik
NPI 1518082510
$52,691.08
in general payments reported to CMS, 2019-2025
14 companies · $29K in 2025
The $29K reported for 2025 was more than what 86% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2021: $21.01 · 2022: $339 · 2023: $3,646 · 2024: $362 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $4,358 · Travel and Lodging: $1,492 · Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,248.00 |
| Consulting Fee | $4,357.50 |
| Travel and Lodging | $1,492.33 |
| Food and Beverage | $1,363.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23,161.59 | 2019-2025 | Livdelzi |
| Ipsen Biopharmaceuticals, INC | $16,604.93 | 2023-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $12,385.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Conmed Corporation | $130.46 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $120.61 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $118.78 | 2023 | Rebyota |
| Celgene Corporation | $46.19 | 2021-2022 | |
| Novo Nordisk INC | $32.40 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.09 | 2022 | |
| Janssen Biotech, INC. | $21.72 | 2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $21.32 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.26 | 2025 | Terlivaz |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.